OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Loren Scott Michel on HPV-Associated Oropharyngeal Cancer

April 1st 2015

Loren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.

Dr. Garcia on Challenges With Immunotherapy in Prostate Cancer

April 1st 2015

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

Dr. Joseph on Necessary Improvements on Immunotherapy in Melanoma

March 31st 2015

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Dr. Balar on Phase III ASSURE Trial Results

March 31st 2015

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

Dr. Jedd Wolchok on Immunotherapy Toxicities

March 30th 2015

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

Dr. Kaufman on the Potential of T-VEC for Advanced Melanoma

March 30th 2015

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Rutgers Cancer Institute of New Jersey, discusses the use of oncolytic viruses for the treatment of advanced melanoma.

Dr. Van Tine on Sequencing Therapies in GIST

March 27th 2015

Brian Van Tine, MD, PhD, assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses sequencing in gastrointestinal stromal tumors (GIST).

Dr. Alan Miller on Immunotherapy for Cancer Treatment

March 26th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

Dr. Dawson on Increasing Causes and Unmet Needs in HCC

March 26th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, discusses increasing cause of hepatocellular carcinoma (HCC) and unmet needs related to the disease.

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Dr. Lynch on Expanding Molecular Subsets in NSCLC

March 25th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Sam Donaldson on the Need for Optimistic Doctors

March 24th 2015

Former ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.

Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

March 24th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Dr. Bijal Shah on Bortezomib's Impact on Treatment of MCL

March 24th 2015

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Dr. Lacouture On Preventing Dermatological Adverse Events in Melanoma

March 23rd 2015

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

Dr. Weber on Molecular Testing in Melanoma

March 23rd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the significance of molecular testing for patients with melanoma and when testing should occur.

Dr. Wierda on RESONATE-2 Trial Predictions for Patients With CLL

March 20th 2015

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL).

Dr. Battiste on Biomarkers in Glioblastoma

March 19th 2015

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

Dr. Koo on Active Surveillance Rates in Prostate Cancer

March 19th 2015

Alec Koo, MD, FACS, managing partner, Skyline Urology, board of directors, LUGPA, discusses results from a recent study on active surveillance in prostate cancer.

Dr. Phan Discusses Challenges With Treating pNETs

March 19th 2015

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).